Back to results
US 2013/0274265 A1Published application
Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
AssigneesShionogi & Co., Ltd., Purdue Pharma L.P.
InventorsKouki FUCHINO, Naoki TSUNO, John W.F. WHITEHEAD, Jiangchao YAO
Life of this patent
Estimating the term…
Abstract
Compounds of Formula (I): where R1, R2, R5, a, and b are disclosed herein, and pharmaceutically acceptable derivatives thereof (a “Substituted-Quinoxaline-Type Bridged-Piperidine Compound”), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.
Claims53
A compound of Formula (I′):
- or a pharmaceutically acceptable salt thereof wherein:
- each R2 is independently selected from -halo;
- a is an integer selected from 0, 1, and 2;
- b is an integer selected from 0 and 1;
- each R5 is independently —H, —OH, —(C1-C3)alkyl, —C(halo)3, or -halo;
- R1 is —(C9-C14)cycloalkyl or —(C9-C14)bicycloalkyl, each of which is substituted with 1, 2 or 3 independently selected R3 groups;
- each R3 is independently —(C1-C4)alkyl, —(C2-C6)alkenyl, —(C2-C6)alkynyl, or —(C3-C6)cycloalkyl;
- and
- each halo is independently —F, —Br, or —I.
6 more elements
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof wherein:
- each R2 is independently selected from -halo;
- a is an integer selected from 0, 1, and 2;
- b is an integer selected from 0 and 1;
- each R5 is independently —H, —OH, —(C1-C3)alkyl, —C(halo)3, or -halo;
- R1 is —(C9-C14)cycloalkyl or —(C9-C14)bicycloalkyl, each of which is unsubstituted;
- and
- each halo is independently —F, —Cl, —Br, or —I.
5 more elements
Dependencies are inferred from the claim text.